CuraSen Therapeutics has reported positive results from a Phase II clinical trial with oral, brain-permeant beta2 adrenoceptor (β2-AR) agonist, CST-103, in patients with Parkinson’s disease (PD) or mild cognitive impairment (MCI).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,